Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470473 | 0.83 | ALDH1A1 (0.47) | ALDH1A1CYP3A4IDO1EP300KAT8 | |
| SCHEMBL9123318 | 0.81 | MAPT (0.52) | ALDH1A1CYP3A4TDP1HSD17B10TSHR | |
| SCHEMBL2123973 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CYP3A4IDO1EP300KAT8 | |
| SCHEMBL2656026 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CYP3A4IDO1EP300KAT8 | |
| SCHEMBL7861678 | 0.77 | HIF1A (0.55) | ALDH1A1CYP3A4HSD17B10TSHRLMNA | |
| SCHEMBL9275892 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TDP1HSD17B10TSHR | |
| SCHEMBL28056190 | 0.77 | IDO1 (0.44) | ALDH1A1CYP3A4IDO1EP300KAT8 | |
| SCHEMBL2549340 | 0.77 | IDO1 (0.44) | ALDH1A1CYP3A4IDO1EP300KAT8 | |
| SCHEMBL1801222 | 0.76 | CYP3A4 (0.48) | ALDH1A1CYP3A4IDO1EP300KAT8 | |
| SCHEMBL25009959 | 0.76 | ALDH1A1 (0.48) | ALDH1A1CYP3A4IDO1EP300KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162871-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| EP-3856176-A2 | INHIBITORS OF VAP-1 | Acucela Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164454-A | Inhibitors of VAP-1 | 奥克塞拉有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020069330-A2 | INHIBITORS OF VAP-1 | ACUCELA INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-3029024-A1 | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity | Ferrer Internacional, S.A. (ES) | 2016-06-08 | — | — | EP | disclosed |
| WO-2000066613-A1 | BONE TARGETING AGENTS FOR OSTEOPOROSIS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787791-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | ALDH1A1 869/4885CYP3A4 4363/4885IDO1 4231/4885 |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ALDH1A1 869/4885CYP3A4 4363/4885IDO1 4231/4885 |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ALDH1A1 869/4885CYP3A4 4363/4885IDO1 4231/4885 |
| US-12162871-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | ALDH1A1 869/4885CYP3A4 4363/4885IDO1 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.